Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Modified Basophil Activation Test for the Clinical Management of Immediate Hypersensitivity Reactions to Paclitaxel: A Proof-of-Concept Study.
La Sorda M, Fossati M, Graffeo R, Ferraironi M, De Rosa MC, Buzzonetti A, Righino B, Zampetti N, Fattorossi A, Nucera E, Aruanno A, Ferrandina G, Apostol AI, Buonomo A, Scambia G, Sanguinetti M, Battaglia A. La Sorda M, et al. Among authors: buzzonetti a. Cancers (Basel). 2023 Dec 13;15(24):5818. doi: 10.3390/cancers15245818. Cancers (Basel). 2023. PMID: 38136365 Free PMC article.
PD-L1 Expression on Circulating Tumour-Derived Microvesicles as a Complementary Tool for Stratification of High-Grade Serous Ovarian Cancer Patients.
Battaglia A, Piermattei A, Buzzonetti A, Pasciuto T, Zampetti N, Fossati M, Angelico G, Iacobelli V, Nero C, Iannucci V, Scambia G, Fagotti A, Fattorossi A. Battaglia A, et al. Among authors: buzzonetti a. Cancers (Basel). 2021 Oct 16;13(20):5200. doi: 10.3390/cancers13205200. Cancers (Basel). 2021. PMID: 34680346 Free PMC article.
Correction to: Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients.
Battaglia A, Buzzonetti A, Fossati M, Scambia G, Fattorossi A, Madiyalakan MR, Mahnke YD, Nicodemus C. Battaglia A, et al. Among authors: buzzonetti a. Cancer Immunol Immunother. 2020 Jul;69(7):1389. doi: 10.1007/s00262-020-02537-4. Cancer Immunol Immunother. 2020. PMID: 32219502 Free PMC article.
Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients.
Battaglia A, Buzzonetti A, Fossati M, Scambia G, Fattorossi A, Madiyalakan MR, Mahnke YD, Nicodemus C. Battaglia A, et al. Among authors: buzzonetti a. Cancer Immunol Immunother. 2020 Mar;69(3):383-397. doi: 10.1007/s00262-019-02456-z. Epub 2020 Jan 3. Cancer Immunol Immunother. 2020. PMID: 31897661 Free PMC article. Clinical Trial.
44 results